Parkinson's Disease (PD)

Parkinson's disease (PD) is a neurodegenerative disease characterized by movement disorder symptoms and a series of non-motor complications. The main clinical behavioral characteristics include bradykinesia, resting tremor, rigidity, and gait abnormalities. Pathological features include degeneration of dopaminergic neurons in the substantia nigra pars compacta, decreased dopamine secretion in the striatum, and Lewy body accumulation. GemPharmatech has developed four PD models for the screening and safety evaluation of Parkinson's disease therapies.

50+
Mouse Models Related to Neurological Diseases
500+
Studies Completed
10+
ND-Enabling Studies

Advantages

Our Advantages

Clinically Relevant Models

Our PD models faithfully replicate key pathological features of Parkinson's disease, including dopaminergic neuron degeneration in the substantia nigra, decreased dopamine secretion in the striatum, and α-synuclein aggregation — providing clinically predictive platforms for drug efficacy evaluation.

Comprehensive Assessment

We offer a full spectrum of behavioral and biochemical assessments — rotarod, grip strength, gait analysis, neurochemical analysis, and histopathology — to comprehensively characterize drug effects across all PD models.

Customizable Study Design

From model selection to experimental endpoints, our team works closely with sponsors to tailor study protocols that align with specific research goals and regulatory requirements for Parkinson's disease therapies.

Model Library

Case Studies

Case Studies & Validation Data

AAV-GDNF Therapeutic Efficacy

AAV-GDNF Treatment Improves Limb Muscle Strength and Motor Coordination in B6-hSNCA A53T/E46K Mice

Learn more

AAV-GDNF Treatment Improves Limb Muscle Strength and Motor Coordination in B6-hSNCA A53T/E46K Mice

Panel A: Experimental design of AAV virus injection to assess therapeutic effects on motor function.

Panel B: Body weight changes in B6-hSNCA E46K/A53T mice following AAV virus injection.

Panel C: Changes in limb grip strength of B6-hSNCA E46K/A53T mice 42 days after virus injection.

Panel D: Changes in latency to fall during the rotarod test 70 days after virus injection.

Data are presented as Mean ± SEM (n = 12/group). Statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; One-way ANOVA.

6-OHDA-Induced PD Mouse Model

Experimental Design

Learn more

4 weeks after unilateral stereotaxic injection of 6-OHDA, subcutaneous injection of apomorphine (0.5 mg/kg) will cause mice to rotate toward the uninjured side. Mice that rotate more than 120 times (4 turns/minute) within 30 minutes can be identified as PD models.

2. Behavioral Test-- Open Field Test

Learn more

PD mice did not show decreased locomotor activity and anxiety-like behavior in the open field test.

n=10 mice/group. Data are represented as mean ± SEM. T-test was performed to determine the statistical significance between 2 groups. *P<0.05,**P<0.01,***P<0.001,****P<0.0001. P<0.05 was considered statistically significant.

3. Behavioral Test - Rotarod

Learn more

PD mice showed deficits in motor learning and motor coordination in the rotarod test.

4. Behavioral Test - Pole Test

Learn more

PD mice showed bradykinesia and reduced motor coordination in the pole test.

5. Behavioral Test - Gait Analysis

Learn more

4 weeks after 6-OHDA injection, gait analysis showed that PD mice exhibited significant bradykinesia.

n=8-10 mice/group. Data are represented as mean ± SEM. T-test was performed to determine the statistical significance between 2 groups. *P<0.05,**P<0.01,***P<0.001,****P<0.0001. P<0.05 was considered statistically significant.

6. Pathology-- TH(+) Neurons in the Substantia Nigra and Striatum

Learn more

5, 9, and 12 weeks after 6-OHDA injection, TH(+) neuron loss was observed in the striatum and substantia nigra on the injured side of PD mice.

n=4-10 mice/group. Data are represented as mean ± SEM. T-test was performed to determine the statistical significance between 2 groups. *P<0.05,**P<0.01,***P<0.001,****P<0.0001. P<0.05 was considered statistically significant.

7. Pathology-- Number of IBA1(+) Microglia in the Cortex and Striatum

Learn more

No significant increase in the number of IBA1(+) microglia in the cortex and striatum of PD mice.

n=6 mice/group. Data are represented as mean ± SEM. T-test was performed to determine the statistical significance between 2 groups. *P<0.05,**P<0.01,***P<0.001,****P<0.0001. P<0.05 was considered statistically significant.